Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alpine Immune Sciences Inc.

http://www.alpineimmunesciences.com/

Latest From Alpine Immune Sciences Inc.

Deal Watch: BMS Licenses Bispecific TCR Candidate From Immatics

BioMarin teams with Skyline on gene therapies for cardiovascular disease. Myrtelle discloses licensing of gene therapy for Canavan disease from Pfizer earlier in 2021.

Deal Watch Business Strategies

Combined AbbVie/Allergan Makes Earnings Debut

The merger closed in May, so the second quarter earnings report will be the first presentation of the combined company’s performance and outlook.

Sales & Earnings Business Strategies

AbbVie’s Rinvoq Shines In First Of Three Eczema Pivotal Studies

The JAK1 inhibitor showed skin clearance and itch reduction in first of three Phase III trials. Analysts say blockbuster atopic dermatitis indication is possible if data hold up in ongoing studies.

Clinical Trials Business Strategies

AbbVie Pays $60m To Option Alpine’s Lupus Candidate

Deal Snapshot: Set to begin a Phase II study that Alpine will complete, ALPN-101 is a dual inhibitor of CD28 and ICOS that may offer a new treatment option in SLE.

Deals Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • N30 Pharmaceuticals, Inc.
    • Nivalis Therapeutics, Inc.
UsernamePublicRestriction

Register